Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Emtricitabine / rilpivirine / tenofovir alafenamide (Odefsey®) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV-1 RNA copies/ml. |
|||
|
|||
Medicine details |
|||
| Medicine name | emtricitabine / rilpivirine/tenofovir alafenamide (Odefsey®) | ||
| Formulation | 200 mg / 25 mg / 25 mg film-coated tablet | ||
| Reference number | 3031 | ||
| Indication | Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV-1 RNA copies/ml |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 3316 | ||
| NMG meeting date | 05/10/2016 | ||
| AWMSG meeting date | 09/11/2016 | ||
| Ratification by Welsh Government | 18/11/2016 | ||
| Date of issue | 21/11/2016 | ||
| Date of last review | July 2020 | ||